- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
J Clin Microbiol. 2018 Oct 24. pii: JCM.01303-18. doi: 10.1128/JCM.01303-18. [Epub ahead of print]
HBcrAg correlated with intrahepatic HBV tDNA and cccDNA in HBeAg-positive chronic hepatitis B patients.
Wang L1, Cao X1, Wang Z1, Gao Y1, Deng J1, Liu X2, Zhuang H2.
Author information
1
Department of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
2
Department of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China. [email protected] [email protected]).
Abstract
This study was to explore the correlation of serum hepatitis B core-related antigen (HBcrAg) with intrahepatic HBV covalently closed circular DNA (cccDNA) and HBV total DNA (tDNA) in HBeAg-positive chronic hepatitis B (CHB) patients. Serum HBcrAg and other parameters including HBV DNA, HBV RNA, HBeAg, HBsAg, anti-HBc, ALT, AST were quantitatively measured at baseline and follow-up time points. Intrahepatic HBV cccDNA and tDNA were quantitatively detected at baseline and 96-week. Grading of liver necroinflammation and staging of hepatic fibrosis were assessed at baseline and 96-week. Correlations between serum HBcrAg and other parameters were analyzed by Pearson's correlation analysis. The results showed that pre-treatment HBcrAg correlated significantly with HBV tDNA level (r=0.328, P=0.003) in 82 CHB patients, and intrahepatic HBV cccDNA (r=0.323, P=0.004) (n=79) after removing three outliers. Serum HBcrAg correlated better with HBV cccDNA in patients with lower level of serum HBV DNA (stratified by 7 log IU/ml of HBV DNA: r=0.656, P=0.003 vs. r=-0.02, P=0.866). Significant inverse correlations were found between HBcrAg and grade of liver necroinflammation (r=-0.245, P=0.037), stage of hepatic fibrosis (r=-0.360, P=0.002) at baseline. Serum HBcrAg presented significant correlation with intrahepatic HBV cccDNA in patients with HBeAg seroconversion at 96-week (r=0.622, P=0.006). The decline in HBcrAg showed significant correlation with the decline in HBV cccDNA after 96-week NAs therapy (r=0.282, P=0.043). Serum HBcrAg also correlated significantly with other serum markers at baseline and 96-week of NAs therapy. In conclusion, baseline HBcrAg and its declined value were significantly correlated with the corresponding intrahepatic HBV cccDNA.
PMID:
30355757
DOI:
10.1128/JCM.01303-18
|
|